Alibaba Health Surges 13% On Strong FY Earnings By Investing.com | Old North State Wealth News
Connect with us

Investing

Alibaba Health surges 13% on strong FY earnings By Investing.com

Published

on

Investing.com– Shares of Alibaba Health Information Technology (HK:) rose sharply on Tuesday after the firm clocked a sharp jump in its annual earnings on improved margins and strong demand for healthcare services and pharmaceuticals on its platforms. 

The firm, which was acquired by e-commerce giant Alibaba Group (HK:) (NYSE:) in 2014, rose as much as 13.7% to HK3.55- a two-month high. It was also the top gainer on the index, which rose 0.6%. 

Alibaba Health’s adjusted net profit for the year to March 31, 2024, surged nearly 91% to 1.44 billion yuan ($200 million).

Revenue rose about 1% to 27.03 billion yuan, as sales appeared to be stagnating after COVID-led demand sparked stellar sales growth over the past three years.

But Alibaba Health benefited from improved margins, especially on its online healthcare services, as well as pharmaceutical sales. 

Merchants on its Tmall Healthcare Platform jumped 28% to over 35,000 merchants, while average revenue per user surged 17% year-on-year. 

Going forward, the firm said that 2024 was likely to be a challenging year on the macro front. But it also flagged plans to lean further into the internet health industry, particularly in setting up cloud infrastructure for Chinese hospitals.

The firm also said it will explore the application of artificial intelligence through “large speech models.” 



Read the full article here

Advertisement

Trending

Copyright © 2022 ONSWM News. Content posted on the Old North State Wealth News page was developed and produced by a third party news aggregation service. Old North State Wealth Management is not affiliated with the news aggregation service. The information presented is believed to be current. It should not be viewed as personalized investment advice. All expressions of opinion reflect the judgment of the authors on the date the articles were published. The information presented is not an offer to buy or sell, or a solicitation of any offer to buy or sell, any of the securities discussed.